公司代码：600530 公司简称：交大昂立 第一节 重要提示 2.1公司简介 ■ 2.2主要财务数据 单位：元 币种：人民币 1.1本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到http://www.sse.com.cn网站仔细阅读半年度报告全文。 1.2本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 1.3公司全体董事出席董事会会议。 1.4本半年度报告未经审计。 1.5董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 第二节 公司基本情况 □适用 √不适用 2.6在半年度报告批准报出日存续的债券情况 □适用 √不适用 ■ 2.3前10名股东持股情况表 单位: 股 ■ 2.4截至报告期末的优先股股东总数、前10名优先股股东情况表 □适用 √不适用 2.5控股股东或实际控制人变更情况 第三节 重要事项 公司应当根据重要性原则，说明报告期内公司经营情况的重大变化，以及报告期内发生的对公司经营情 况有重大影响和预计未来会有重大影响的事项 ...

Core Points - Shanghai Jiao Tong University Anli Co., Ltd. reported a decrease in total assets by 2.89% to CNY 736.93 million compared to the previous year [1] - The net profit attributable to shareholders decreased by 30.54% to CNY 2.25 million, while total profit dropped by 19.06% to CNY 6.99 million [1] - The company experienced a significant decline in operating revenue, which fell by 5.77% to CNY 150.77 million [1] Financial Summary - Total assets at the end of the reporting period were CNY 736,926,378.63, down from CNY 758,879,487.15 [1] - Net assets attributable to shareholders decreased to CNY 318,812,621.60 from CNY 325,711,012.85, a reduction of 2.12% [1] - The net cash flow from operating activities was negative at CNY -9,486,541.87, a decline of 143.71% compared to the previous year [1] - The weighted average return on net assets decreased by 0.39 percentage points to 0.70% [1] - Basic and diluted earnings per share both fell by 30.95% to CNY 0.0029 [1] Shareholder Information - The total number of shareholders at the end of the reporting period was 26,322 [1] - Major shareholders include Shanghai Yun Jian Industrial Development Co., Ltd. with a 12.14% stake and Shanghai New Road Commercial (Group) Co., Ltd. with a 6.19% stake [2] - A group of shareholders, including Shanghai Yun Jian and others, collectively holds 30.06% of the company's total share capital [2] Important Events - The company faced significant operational challenges due to a lawsuit against a non-profit organization, which resulted in an unfavorable first-instance judgment. The company has appealed this decision [4]

Core Viewpoint - Shanghai Jiaoda Onlly Co., Ltd. reported a decline in key financial metrics for the first half of 2025, indicating challenges in revenue generation and profitability amidst a competitive market environment [1][2]. Financial Performance - The company's operating revenue for the first half of 2025 was CNY 150.77 million, a decrease of 5.77% compared to CNY 160.01 million in the same period last year [2]. - Total profit for the period was CNY 6.99 million, down 19.06% from CNY 8.64 million year-on-year [2]. - Net profit attributable to shareholders was CNY 2.25 million, reflecting a 30.54% decline from CNY 3.24 million in the previous year [2]. - The net cash flow from operating activities was negative at CNY -9.49 million, a significant drop from CNY 21.70 million in the same period last year, marking a 143.71% decrease [2]. - Total assets decreased by 2.89% to CNY 736.93 million from CNY 758.88 million at the end of the previous year [2]. Business Overview - The primary business segments include the research, production, and sales of health products, health food, and health product raw materials, as well as the operation and management of elderly medical care institutions [3][5]. - The health product segment focuses on probiotics and plant extracts, with a diverse product line aimed at various health needs [3]. - The company has established a strong presence in the health industry, which is projected to grow significantly, with the total revenue expected to exceed CNY 9 trillion by 2024 and reach CNY 16 trillion by 2030, reflecting a compound annual growth rate of approximately 12% [3]. Market Position and Strategy - The company emphasizes research and development, having launched new products such as probiotic personal care items and pet nutrition supplements during the reporting period [3][5]. - The health product raw materials business is facing increased competition, prompting the company to optimize its workforce and improve production processes to enhance efficiency [5]. - The elderly care segment operates six self-managed profit-oriented medical care institutions, providing a range of services including medical care, rehabilitation, and daily living support [5][6]. Competitive Advantages - The company possesses a robust platform for probiotics and plant extraction resources, supported by extensive research collaborations with academic institutions [6]. - It has received numerous accolades, enhancing its brand recognition and consumer loyalty in the health product market [6]. - The company maintains a comprehensive quality control system and has achieved various certifications, ensuring product safety and efficacy [6].

Core Viewpoint - The company, Jiaoda Onlly (交大昂立), reported a decline in both revenue and net profit for the first half of 2025, alongside being under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations [1][2]. Financial Performance - The company achieved a revenue of 151 million yuan, a year-on-year decrease of 5.77% [1]. - The net profit attributable to shareholders was 2.25 million yuan, down 30.54% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was -2.13 million yuan, indicating an increase in losses compared to the previous year [1]. Business Segments - The main business areas of the company include the research, production, and sales of health products, as well as the operation and management of elderly medical care institutions [1]. - In the 2024 annual report, the revenue contributions from health products, real estate, and medical care businesses were 48.45%, 5.01%, and 45.33%, respectively [1]. Challenges and Legal Issues - The health product segment faced a slight decline due to intensified competition in the domestic probiotic industry and changes in tariff policies in North America [2]. - The medical care segment has encountered issues as various non-profit institutions unilaterally terminated management consulting agreements and refused to pay management fees, leading the company to file lawsuits [2]. - The company received a notice from the CSRC regarding an investigation for suspected violations of information disclosure laws [2].

（文章来源：证券日报） 证券日报网讯 7月30日晚间，交大昂立发布公告称，2025年上半年实现归属于上市公司股东的净利润 2，248，634.38元。 ...

交大昂立（SH 600530，收盘价：8.88元）7月30日晚间发布半年度业绩报告称，2025年上半年营业收入 约1.51亿元，同比减少5.77%；归属于上市公司股东的净利润约225万元，同比减少30.54%；基本每股收 益0.0029元，同比减少30.95%。 （文章来源：每日经济新闻） ...

智通财经APP讯，交大昂立(600530.SH)发布2025年半年度报告，报告期内，公司实现营业收入1.51亿 元，同比下降5.77%。实现归属于上市公司股东的净利润224.86万元，同比下降30.54%。归属于上市公 司股东的扣除非经常性损益净亏损212.85万元。基本每股收益0.0029元。 ...

Section I Definitions [Definitions of Common Terms](index=4&type=section&id=Definitions%20of%20Common%20Terms) This section provides definitions for key terms and abbreviations, including the company, affiliates, and regulatory bodies, essential for report comprehension - The report clarifies the designations of core companies and related parties such as **"Jiaoda Onlly," "Shanghai Yunjian," and "Dazhong Transportation"**[12](index=12&type=chunk) Section II Company Profile and Key Financial Indicators [Company Information](index=4&type=section&id=Company%20Information) This section provides the company's fundamental business registration details, including names, legal representative, and contact information - The company's full name is **Shanghai Jiaoda Onlly Co., Ltd.**, stock code **600530**, and legal representative is **Ji Min**[14](index=14&type=chunk)[19](index=19&type=chunk) [Key Accounting Data and Financial Indicators](index=5&type=section&id=Key%20Accounting%20Data%20and%20Financial%20Indicators) In H1 2025, the company experienced a performance decline with revenue down 5.77% and net profit attributable to shareholders decreasing by 30.54%, while operating cash flow turned negative, indicating significant cash flow pressure Key Accounting Data for H1 2025 | Item | Current Period (Jan-Jun) | Prior Period | Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 150,774,339.60 RMB | 160,012,804.82 RMB | -5.77% | | Net Profit Attributable to Shareholders of Listed Company | 2,248,634.38 RMB | 3,237,508.43 RMB | -30.54% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-recurring Gains/Losses) | -2,128,457.43 RMB | -1,137,481.09 RMB | N/A | | Net Cash Flow from Operating Activities | -9,486,541.87 RMB | 21,701,949.08 RMB | -143.71% | | Total Assets | 736,926,378.63 RMB | 758,879,487.15 RMB | -2.89% (vs. end of previous year) | | Net Assets Attributable to Shareholders of Listed Company | 318,812,621.60 RMB | 325,711,012.85 RMB | -2.12% (vs. end of previous year) | Key Financial Indicators for H1 2025 | Item | Current Period (Jan-Jun) | Prior Period | Change (%) | | :--- | :--- | :--- | :--- | | Basic Earnings Per Share (RMB/share) | 0.0029 | 0.0042 | -30.95% | | Weighted Average Return on Net Assets (%) | 0.70% | 1.09% | Decreased by 0.39 percentage points | - During the reporting period, non-recurring gains and losses totaled **RMB 4.3771 million**, primarily from the reversal of loan impairment losses of **RMB 2.25 million** from Onlly Microcredit repayment, government subsidies, and non-operating income/expenses[23](index=23&type=chunk) Section III Management Discussion and Analysis [Main Business and Industry Overview](index=7&type=section&id=Explanation%20of%20the%20Company%27s%20Industry%20and%20Main%20Business%20During%20the%20Reporting%20Period) The company's main business comprises two segments: health products and medical care services, operating within the promising big health industry with strong growth prospects in probiotics and plant extracts - The company's main businesses include the **R&D, production, and sales of health products (including raw materials)**, and the **operation and management of elderly medical care institutions**[25](index=25&type=chunk) - The health product segment focuses on **probiotics and plant extracts**, with business models covering **B2C end-product sales and B2B raw material supply**[26](index=26&type=chunk)[27](index=27&type=chunk)[28](index=28&type=chunk) - The medical care segment primarily operates **self-managed elderly care institutions**, providing **medical, rehabilitation, and nursing services** for the elderly, and offers **external management consulting services**[31](index=31&type=chunk) - The industry outlook is broad, with China's big health industry expected to reach **RMB 16 trillion by 2030**, and the **probiotics and plant extract markets** maintaining rapid growth[29](index=29&type=chunk)[30](index=30&type=chunk) [Discussion and Analysis of Operations](index=8&type=section&id=Discussion%20and%20Analysis%20of%20Operations) During the reporting period, the health product segment expanded product lines, but raw material business declined due to competition and tariffs, while the medical care segment faced significant challenges from unilateral termination of management agreements and ongoing litigation - For health product end-products, the company expanded its **pet product line** and launched new **cognitive improvement and sports nutrition health products** on platforms like JD.com and Tmall[32](index=32&type=chunk)[33](index=33&type=chunk) - Raw material business performance slightly declined year-on-year due to **fierce domestic probiotics industry competition and North American tariff policy adjustments**, prompting the company to optimize personnel and production processes for cost reduction and efficiency improvement[34](index=34&type=chunk) - Several non-profit organizations under the medical care segment unilaterally terminated management consulting agreements and refused to pay management fees, preventing the company from obtaining related operating income; the company has filed a lawsuit, lost the first instance, appealed, and the second instance is ongoing, which has a **significant impact on the company's operations**[37](index=37&type=chunk)[59](index=59&type=chunk) [Analysis of Core Competencies](index=9&type=section&id=Analysis%20of%20Core%20Competencies%20During%20the%20Reporting%20Period) The company's core competencies lie in its health product segment's strong R&D, brand recognition, and diverse product lines, and its medical care segment's industry focus, professional service quality, and cost control capabilities - The core competencies of the health product segment include **strong R&D platforms and technologies for probiotics and plant extracts**, with **42 invention patents**; **brand advantages** from honors like "China Well-known Trademark"; a **diversified product line** covering health products, daily necessities, and pet products; and a **quality control system** with multiple international certifications[38](index=38&type=chunk)[39](index=39&type=chunk)[40](index=40&type=chunk)[42](index=42&type=chunk) - The core competencies of the medical care segment include **first-mover scale advantages** from long-term cultivation; a **reputation for high-quality services** from professional operating teams and standardized service systems; and **cost control advantages** established through data analysis systems[43](index=43&type=chunk)[44](index=44&type=chunk)[45](index=45&type=chunk) [Financial Analysis of Main Operations](index=10&type=section&id=Main%20Operating%20Conditions%20During%20the%20Reporting%20Period) This section analyzes the company's financial performance, noting a slight decrease in revenue and costs, a significant increase in R&D expenses, a negative shift in operating cash flow due to increased loan disbursements, and a substantial rise in loans and short-term borrowings Analysis of Major Financial Statement Item Changes | Item | Current Period Amount | Prior Period Amount | Change Ratio (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 150,774,339.60 RMB | 160,012,804.82 RMB | -5.77 | | R&D Expenses | 3,224,872.44 RMB | 2,280,318.27 RMB | 41.42 | | Net Cash Flow from Operating Activities | -9,486,541.87 RMB | 21,701,949.08 RMB | -143.71 | | Loans and Advances | 43,500,000.00 RMB | 4,250,000.00 RMB | 923.53 (vs. end of previous year) | | Short-term Borrowings | 36,026,307.22 RMB | 20,024,444.44 RMB | 79.91 (vs. end of previous year) | - The significant decrease in **net cash flow from operating activities** was primarily due to an **increase in net loans disbursed** by the investment and financing segment during the current period[46](index=46&type=chunk) - The company established a wholly-owned subsidiary, **"Onlly International Trading Co., Ltd."** in Hong Kong, with an actual investment of **HKD 10 million**, aiming to develop cross-border e-commerce and international trade businesses[50](index=50&type=chunk)[51](index=51&type=chunk) Operating Performance of Major Holding and Participating Companies (Unit: RMB Million) | Company Name | Main Business | Operating Revenue | Net Profit | | :--- | :--- | :--- | :--- | | Shanghai Nuode Bio-Industry Co., Ltd. | Natural Plant Products | 45.2254 | 7.0653 | | Shanghai Bairen Yinggang Nursing Home Co., Ltd. | Rehabilitation Medicine, etc. | 29.2502 | 3.2387 | | Ningbo Jiangbei Kangyang Hospital Co., Ltd. | Rehabilitation Medicine, etc. | 23.5923 | 3.2726 | | Shanghai Xuhui Onlly Microcredit Co., Ltd. | Loans | 0.00 | 3.1433 | [Potential Risks](index=14&type=section&id=Potential%20Risks) The company faces specific risks in its health product segment, including intense competition and regulatory changes, while the medical care segment is exposed to policy shifts, rising labor costs, and significant litigation risks from contract disputes - The health product segment faces multiple risks including **industry competition, regulatory policies, talent gaps, cost pressures, and international political situations (tariffs)**[57](index=57&type=chunk) - The medical care segment faces risks from **changes in medical insurance and long-term care insurance policies** and **rising labor costs**; the most significant risk is the **unilateral termination of management agreements by affiliated non-profit organizations** and their refusal to pay, with ongoing litigation potentially preventing the company from continuing to obtain operating income[59](index=59&type=chunk) Section IV Corporate Governance, Environment, and Society [Changes in Directors, Supervisors, and Senior Management](index=15&type=section&id=Changes%20in%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, Mr. Du Gang, a non-independent director, resigned from his positions due to personal reasons on June 26, 2025 - On **June 26, 2025**, non-independent director **Mr. Du Gang resigned** due to personal reasons[61](index=61&type=chunk) [Profit Distribution Plan](index=15&type=section&id=Profit%20Distribution%20or%20Capital%20Reserve%20Conversion%20Plan) The company has no profit distribution or capital reserve conversion plan for the first half of 2025 - No profit distribution or capital reserve conversion is planned for the half-year period[62](index=62&type=chunk) Section V Significant Matters [Fulfillment of Commitments](index=17&type=section&id=Fulfillment%20of%20Commitments) During the reporting period, the acquirer Shanghai Shijie and its concerted parties strictly fulfilled their commitments regarding avoiding horizontal competition and regulating related-party transactions - Commitments made in the acquisition report regarding **avoiding horizontal competition and regulating related-party transactions** were strictly fulfilled[66](index=66&type=chunk)[67](index=67&type=chunk) [Major Litigation and Arbitration Matters](index=19&type=section&id=Major%20Litigation%20and%20Arbitration%20Matters) The company is involved in several major litigations, including a withdrawn civil suit against former executives now a criminal report, and a third-party involvement in a joint venture's debt transfer dispute, with the most critical being ongoing appeals related to management contract disputes with non-profit nursing homes - The company's lawsuit against former directors and senior executives Yang Guoping and others for **damaging company interests** has been withdrawn and converted into a **criminal report to the public security organs**, but it has not been filed, and the company has applied for reconsideration[68](index=68&type=chunk) - The company participated as a third party in the **debt transfer contract dispute case** involving its associate company, **Shanghai Xuhui Onlly Microcredit Co., Ltd.**[68](index=68&type=chunk) [Regulatory Penalties and Rectification Status](index=19&type=section&id=Suspected%20Violations%2C%20Penalties%2C%20and%20Rectification%20Status%20of%20Listed%20Company%2C%20its%20Directors%2C%20Supervisors%2C%20Senior%20Management%2C%20Controlling%20Shareholder%2C%20and%20Actual%20Controller) In January 2025, the company and relevant former senior executives received a regulatory warning from the Shanghai Stock Exchange, prompting the company to implement rectification measures including strengthening internal controls and establishing a new auditor selection system - On **January 2, 2025**, the company and several former senior executives received a **regulatory warning from the Shanghai Stock Exchange**[69](index=69&type=chunk) - The company has undertaken rectification measures, including **strengthening internal controls, streamlining approval processes**, and approving the **"Accountant Firm Selection System"**[70](index=70&type=chunk) [Other Significant Matters](index=23&type=section&id=Explanation%20of%20Other%20Significant%20Matters) On July 11, 2025, the company received a "Notice of Case Filing" from the China Securities Regulatory Commission, indicating an ongoing investigation which the company will actively cooperate with - On **July 11, 2025**, the company received a **"Notice of Case Filing"** (No. CSRC Case Filing [2025] 024) from the China Securities Regulatory Commission, indicating that the company is **under investigation**[77](index=77&type=chunk) Section VI Share Changes and Shareholder Information [Share Capital Change Status](index=23&type=section&id=Share%20Capital%20Change%20Status) During the reporting period, there were no changes in the company's total share capital or share structure - During the reporting period, there were **no changes** in the company's total share capital or share structure[79](index=79&type=chunk) [Shareholder Information](index=23&type=section&id=Shareholder%20Information) As of the end of the reporting period, the company had 26,322 shareholders, with Shanghai Yunjian and its concerted parties holding 30.06% as the largest shareholder, and Dazhong Transportation and its concerted parties holding 19.88% - As of the end of the reporting period, the company had **26,322 common shareholders**[80](index=80&type=chunk) Top Ten Shareholders' Shareholding | Shareholder Name | Shares Held at Period End | Percentage (%) | | :--- | :--- | :--- | | Dazhong Transportation (Group) Co., Ltd. | 112,184,187 | 14.48 | | Shanghai Yunjian Industrial Development Co., Ltd. | 94,048,695 | 12.14 | | Shanghai Shijie Decoration Design Engineering Co., Ltd. | 53,248,817 | 6.87 | | Shanghai Xinluda Commercial (Group) Co., Ltd. | 47,993,727 | 6.19 | | Lishui Xincheng Xinchuang Technology Development Partnership (Limited Partnership) | 45,133,650 | 5.82 | - There are two major concerted party groups among shareholders: **Shanghai Yunjian and its concerted parties** collectively hold **30.06%**; **Dazhong Transportation and its concerted parties** collectively hold **19.88%**[83](index=83&type=chunk) - In **February 2025**, **Shanghai Shijie completed a partial tender offer** for the company, after which its total shareholding with concerted parties reached **30.0620%**[84](index=84&type=chunk)[85](index=85&type=chunk) Section VII Bond-Related Information [Bond Status](index=26&type=section&id=Corporate%20Bonds%20and%20Non-Financial%20Enterprise%20Debt%20Financing%20Instruments) During the reporting period, the company had no outstanding corporate bonds, enterprise bonds, non-financial enterprise debt financing instruments, or convertible corporate bonds - The company has **no outstanding corporate bonds, enterprise bonds, non-financial enterprise debt financing instruments, or convertible corporate bonds**[89](index=89&type=chunk) Section VIII Financial Report [Financial Statements](index=27&type=section&id=Financial%20Statements) This chapter provides the company's unaudited H1 2025 consolidated and parent company financial statements, including balance sheets, income statements, cash flow statements, and statements of changes in owners' equity, showing total assets of RMB 737 million, operating revenue of RMB 151 million, net profit attributable to parent of RMB 2.25 million, and negative operating cash flow of RMB 9.49 million Consolidated Balance Sheet Summary (June 30, 2025) | Item | Amount (RMB) | | :--- | :--- | | Total Assets | 736,926,378.63 | | Total Liabilities | 366,299,579.70 | | Total Owners' Equity Attributable to Parent Company | 318,812,621.60 | Consolidated Income Statement Summary (Jan-Jun 2025) | Item | Amount (RMB) | | :--- | :--- | | Total Operating Revenue | 150,774,339.60 | | Total Profit | 6,995,875.44 | | Net Profit Attributable to Parent Company Shareholders | 2,248,634.38 | Consolidated Cash Flow Statement Summary (Jan-Jun 2025) | Item | Amount (RMB) | | :--- | :--- | | Net Cash Flow from Operating Activities | -9,486,541.87 | | Net Cash Flow from Investing Activities | -158,887.97 | | Net Cash Flow from Financing Activities | -7,800,388.16 | | Net Increase in Cash and Cash Equivalents | -17,440,147.17 | [Significant Accounting Policies and Estimates](index=45&type=section&id=Significant%20Accounting%20Policies%20and%20Estimates) This chapter details the company's significant accounting policies and estimates, including consolidation methods, financial instrument classification, expected credit loss models, inventory valuation, long-term equity investments, revenue recognition, and lease accounting, all in accordance with Chinese accounting standards - Financial statements are prepared on a **going concern basis**, adhering to **Chinese Enterprise Accounting Standards**[124](index=124&type=chunk)[125](index=125&type=chunk)[127](index=127&type=chunk) - The company uses the **expected credit loss model** to accrue impairment provisions for financial assets, and for receivables without significant financing components, it applies a **simplified approach** to measure expected credit losses over their entire lifetime[167](index=167&type=chunk)[176](index=176&type=chunk) - Revenue recognition follows the **new revenue standards**, recognized when the customer obtains control of the related goods or services; health product sales are recognized upon **delivery or settlement** based on different models (buyout, consignment, online); medical care services are recognized **over the period of service provision**[234](index=234&type=chunk)[237](index=237&type=chunk) [Notes to Consolidated Financial Statement Items](index=72&type=section&id=Notes%20to%20Consolidated%20Financial%20Statement%20Items) This chapter provides detailed explanations and data breakdowns for major consolidated financial statement items, highlighting that 40.24% of accounts receivable were fully impaired, loans and advances significantly increased, and a full impairment provision was made for RMB 361 million in operating income rights due to contract disputes - At period-end, the book balance of accounts receivable was **RMB 65.45 million**, of which **RMB 26.34 million (40.24%)** was fully impaired individually due to expected uncollectibility[265](index=265&type=chunk)[266](index=266&type=chunk) - The period-end balance of **loans and advances was RMB 43.50 million**, a significant increase from **RMB 4.25 million** at the beginning of the period, primarily due to new loans disbursed in the current period[299](index=299&type=chunk) - Due to contract disputes with several non-profit organizations, the company has fully accrued impairment provisions for **operating income rights** (listed under other non-current assets) with a book original value of **RMB 361 million**[348](index=348&type=chunk)[349](index=349&type=chunk) - At period-end, the book original value of goodwill was **RMB 193 million**, with impairment provisions of **RMB 83 million**, and a net value of **RMB 54.87 million**, with **no new impairment** recognized during the reporting period[333](index=333&type=chunk)[335](index=335&type=chunk) [Related Parties and Related Party Transactions](index=134&type=section&id=Related%20Parties%20and%20Related%20Party%20Transactions) This chapter discloses the company's related party relationships and transactions, identifying Shanghai Yunjian and its concerted parties as the largest shareholder, noting minor related-party sales, and detailing impaired receivables from non-profit organizations and outstanding loans to an associate - The company's largest shareholder is **Shanghai Yunjian Industrial Development Co., Ltd.** and its concerted parties, collectively holding **30.06%**, with **Mr. Ji Lin** as the ultimate controlling person[444](index=444&type=chunk)[445](index=445&type=chunk) - During the reporting period, the amount of **goods purchase and sales transactions with related parties was small**[447](index=447&type=chunk)[448](index=448&type=chunk) - At period-end, accounts receivable from several affiliated non-profit organizations were **fully impaired**; loans and advances to associate **Shanghai Xuhui Onlly Microcredit Co., Ltd.** had a book balance of **RMB 14 million**, with an impairment provision of **RMB 10.5 million**[456](index=456&type=chunk)[457](index=457&type=chunk) [Commitments and Contingencies](index=140&type=section&id=Commitments%20and%20Contingencies) This chapter discloses the company's significant commitments, primarily a RMB 10 million short-term guaranteed loan, and major contingencies, specifically ongoing appeals in lawsuits with seven non-profit organizations regarding management service agreements, which pose significant uncertainty to future earnings - The company has a **RMB 10 million short-term guaranteed loan**, secured by its wholly-owned subsidiary **Shanghai Nuode Bio-Industry Co., Ltd.**[461](index=461&type=chunk) - The company has a **significant contingency** involving ongoing lawsuits with **seven non-profit organizations** regarding the validity of "Equity Transfer Agreements" and "Management Consulting Service Agreements"; the first instance ruling did not support the company's claims, and the company has appealed, with the second instance still ongoing, which may prevent the company from obtaining related operating income[462](index=462&type=chunk)[463](index=463&type=chunk)[464](index=464&type=chunk)[465](index=465&type=chunk)[466](index=466&type=chunk)[467](index=467&type=chunk)[469](index=469&type=chunk)

格隆汇7月30日丨交大昂立（维权）(600530.SH)公布2025年半年度报告，报告期实现营业收入1.51亿 元，同比下降5.77%；归属于上市公司股东的净利润224.86万元，同比下降30.54%；基本每股收益 0.0029元。 ...

证券之星消息，7月30日食品加工板块较上一交易日上涨0.57%，光明肉业领涨。当日上证指数报收于 3615.72，上涨0.17%。深证成指报收于11203.03，下跌0.77%。食品加工板块个股涨跌见下表： 从资金流向上来看，当日食品加工板块主力资金净流出2534.16万元，游资资金净流出462.48万元，散户 资金净流入2996.64万元。食品加工板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 600073 光明肉业 | | 1800.84万 | 4.20% | 2633.61万 | 6.15% | -4434.44万 | -10.35% | | 603345 安井食品 | | 929.83万 | 2.71% | 33.57万 | 0.10% | -963.40万 | -2.81% | | 001215 千味央厨 | | 715.62万 | 7.40% | -99.48万 | -1.03 ...